Breaking News - The Fly

Open Search

LTRN

Lantern Pharma

$

()

Lantern Pharma reports Q4 EPS (39c), two estimates (40c)

LTRN

3/18/2024 - 16:07pm

Lantern Pharma doses first two patients in LP-284 trial

LTRN

3/15/2024 - 08:04am

Lantern Pharma generates new class of ADCs with cryptophycin drug-payload

LTRN

2/15/2024 - 08:19am

Lantern Pharma receives Orphan Drug Designation from FDA for LP-284

LTRN

11/30/2023 - 08:06am

Lantern Pharma treatment of diffuse large B-cell lymphoma granted orphan status

LTRN

11/28/2023 - 09:49am

Lantern Pharma:Data on for LP-184 for GBM published in Clinical Cancer Research

LTRN

10/3/2023 - 08:16am

Lantern Pharma announces first patient dosed in Phase 1 study for LP-184

LTRN

9/25/2023 - 08:31am

Lantern Pharma announces FDA clearance of LP-284 IND application

LTRN

9/18/2023 - 09:10am

Lantern Pharma receives notice of allowance from USPTO for ATRT treatment

LTRN

8/14/2023 - 08:42am

Lantern Pharma reports Q2 EPS (44c), consensus (43c)

LTRN

8/9/2023 - 16:05pm

Lantern Pharma announces FDA clearance for LP-184 IND

LTRN

6/12/2023 - 08:33am

Lantern Pharma announces collaboration with Bielefeld University

LTRN

6/8/2023 - 09:04am

Lantern Pharma assumed with a Buy at EF Hutton

LTRN

5/25/2023 - 07:25am

Lantern Pharma initiated with a Neutral at H.C. Wainwright

LTRN

5/18/2023 - 06:05am